Vitamin K2: The Overlooked Vitamin for Your Heart and Bones

This article contains affiliate links. We only recommend products we have independently researched. Reviewed by the HealthyMag Editorial Team. Last updated: July 2026.

You have probably heard of vitamin D and maybe calcium for your bones. But there is a quieter partner in that story that most people — and many clinicians — overlook: vitamin K2. It does not get the headlines, yet the research linking it to both cardiovascular and skeletal health is some of the more intriguing nutritional science of the past two decades. The catch is that K2 is genuinely hard to get from a Western diet, and it works in ways that are easy to confuse with its better-known cousin, vitamin K1.

This article walks through what vitamin K2 actually is, the biological mechanism that makes it interesting, what the human evidence does and does not show, and how to think about food, supplements, and — critically — safety. We will be honest throughout about where the evidence is strong (randomized trials) and where it is only suggestive (population studies).

What Vitamin K2 Actually Is: K1 vs K2, MK-4 vs MK-7

“Vitamin K” is not one molecule but a family. It splits into two main branches:

• Vitamin K1 (phylloquinone) — found in leafy greens like kale, spinach, and broccoli. This is the form your body uses primarily for blood clotting, and it makes up the bulk of dietary vitamin K in most diets.
• Vitamin K2 (menaquinone) — found in fermented foods and some animal products, and produced in small amounts by gut bacteria. K2 is the form more strongly implicated in directing calcium metabolism outside the liver.

Vitamin K2 itself comes in several subtypes, named MK-4 through MK-13 based on the length of their side chain. Two matter most for consumers:

• MK-4 — a shorter-chain form found in animal foods (egg yolk, butter, liver, some meats). Your body can also convert a little K1 into MK-4. It has a very short half-life in the bloodstream — hours.
• MK-7 — a longer-chain form produced by bacterial fermentation, most famously in the Japanese dish natto. MK-7 stays in circulation far longer (a half-life measured in days rather than hours), which is why it is the form used in most modern once-daily supplements and most of the well-known clinical trials.

This distinction matters because when researchers found a heart benefit, they found it specifically for the menaquinone (K2) family — not for K1. That specificity is a recurring theme in the data.

How It Works: Matrix Gla Protein and the Calcium Traffic Cop

Here is the mechanism that makes vitamin K2 worth caring about. Your body makes a protein called matrix Gla protein (MGP), which lives in the walls of your arteries. When MGP is switched on, it acts as one of the body’s most important local brakes on vascular calcification — it binds calcium crystals and stops them from hardening arterial walls.

But MGP does not switch itself on. It has to be “carboxylated” — chemically activated — and that reaction absolutely requires vitamin K as a cofactor for the enzyme that does the job. Without enough vitamin K, MGP stays in its inactive, uncarboxylated form, which is associated with more calcification and cardiovascular disease. In animal studies, animals bred to lack functional MGP die young from arteries so calcified they rupture.

A parallel process happens in bone. A protein called osteocalcin also needs vitamin K to be activated so it can bind calcium into the bone matrix. So the elegant, and still partly hypothetical, model is this: adequate vitamin K2 helps activate both proteins, effectively acting as a “traffic cop” that directs calcium into bone where you want it and away from arteries where you do not. This is also why vitamin K antagonist drugs like warfarin — which block this exact pathway — are associated with increased arterial calcification. We will return to that under safety.

The Heart Evidence: The Rotterdam Study and Calcification

The most cited piece of cardiovascular evidence is the Rotterdam Study (Geleijnse and colleagues, published in The Journal of Nutrition in 2004). Researchers followed 4,807 adults with no history of heart attack, tracking their diet and outcomes for roughly a decade.

The finding was striking: people in the highest third of dietary menaquinone (K2) intake had a relative risk of coronary heart disease mortality of 0.43 compared with the lowest third — roughly a 50% lower risk of dying from heart disease (95% confidence interval 0.24 to 0.77). High K2 intake was also linked to less severe aortic calcification and lower all-cause mortality. Critically, vitamin K1 intake showed no relationship with any of these outcomes — reinforcing that this appears to be a K2-specific signal.

An honest caveat: the Rotterdam Study is observational. It shows association, not proof of cause. People who eat more K2-rich foods may differ in other ways. Association studies like this generate hypotheses; they do not settle them.

To move toward cause, researchers ran controlled trials on vascular markers. In a 3-year randomized, double-blind, placebo-controlled trial (Knapen and colleagues, Thrombosis and Haemostasis, 2015), 244 healthy postmenopausal women took either 180 mcg/day of MK-7 or placebo. The MK-7 group saw improvements in arterial stiffness measures (including pulse wave velocity) over three years, while the placebo group did not. It is a modest, mechanism-consistent result on a surrogate marker — not proof of fewer heart attacks — but it is a genuine randomized trial pointing in the same direction as the population data. If heart health is your focus, you may also want to read our deep dive on CoQ10 for heart health and statin users.

The Bone Evidence: MK-7 Randomized Trials

The skeletal data include stronger trial evidence. In the same 3-year cohort, Knapen and colleagues (Osteoporosis International, 2013) randomized 244 healthy postmenopausal women to 180 mcg/day MK-7 or placebo. The MK-7 group showed:

• A significantly slower age-related decline in bone mineral density at the lumbar spine and femoral neck (hip).
• Measurable improvements in bone strength indicators and reduced loss of vertebral height.
• More than a 50% reduction in uncarboxylated osteocalcin — direct biochemical proof that the supplement was activating the vitamin-K-dependent bone protein as the mechanism predicts.

A separate 3-year randomized, placebo-controlled trial in postmenopausal women with osteopenia (published in Osteoporosis International in 2020) examined MK-7’s effect on bone density and microarchitecture, adding to the picture that this is an actively studied — not fringe — area.

The reasonable takeaway: for bone loss in postmenopausal women, MK-7 at around 180 mcg/day has real randomized-trial support for slowing decline and improving bone-quality markers. It is a complement to, not a replacement for, established bone therapy.

Why K2 and D3 Belong Together

Vitamin D3 and vitamin K2 are best understood as a team, and the logic follows directly from the mechanism above. Vitamin D3 improves how much calcium your body absorbs from the gut. That is good — but absorbing more calcium raises an obvious question: where does that calcium go?

This is where K2 comes in. K2 activates the proteins (osteocalcin and matrix Gla protein) that determine calcium’s destination — into bone, away from arteries. In theory, taking high-dose D3 without adequate K2 could increase circulating calcium without fully ensuring it is routed correctly. That is the rationale behind the popular D3+K2 combination products. It is a biologically sensible pairing, though it is worth stating plainly that large trials proving the combination reduces fractures or heart attacks in the general population are still limited. The synergy is well-reasoned mechanistically and supported by the marker data, rather than proven at the hard-outcome level.

Food Sources: Natto, Cheese, and Egg Yolk

The uncomfortable truth about vitamin K2 is that most Western diets contain very little of it. The single richest source by a wide margin is natto, a fermented soybean dish that is an acquired taste for many. After that, aged cheeses and certain animal products contribute modest amounts. Note that values vary considerably depending on fermentation, animal diet, and measurement method.

For context, national guidelines set an adequate intake for total vitamin K of about 120 mcg/day for adult men and 90 mcg/day for adult women — but those targets were built around K1 and clotting, not around the higher-dose K2 used in the bone and vascular trials. Unless you eat natto regularly, hitting meaningful K2 levels from food alone is genuinely difficult. Whole-diet basics still matter for cardiovascular health too — see our look at beetroot juice for blood pressure for another food-first angle.

Dosage and What to Look For

Based on the trials above, the most-studied and commonly recommended supplemental dose is MK-7 at roughly 90–180 mcg/day. MK-7 is preferred over MK-4 in most modern products because of its long half-life, which allows effective once-daily dosing — the 180 mcg MK-7 dose is exactly what the 3-year bone and arterial trials used.

When comparing products, a few practical criteria separate serious supplements from filler:

• Form: Look for MK-7 (often listed as menaquinone-7), ideally noting the trans-isomer, which is the biologically active configuration.
• Paired with D3: Because of the calcium-routing synergy, many people choose a combined D3 + K2 product. This is a reasonable, mechanism-based choice.
• Third-party tested: Since supplements are loosely regulated, independent verification (USP, NSF, or a published certificate of analysis) is the single best signal of label accuracy.
• Fat with dosing: K2 is fat-soluble, so absorption improves when taken with a meal containing some fat.

A well-formulated third-party-tested MK-7 (with or without D3) is what we look for when evaluating products in this category. As always, a supplement is an addition to — not a substitute for — a nutrient-dense diet. If your broader goal is healthy aging, you may also find our review of omega-3s and aging muscle useful alongside K2.

Safety and Who Should Be Cautious

For most healthy people, vitamin K2 has an excellent safety profile, and no tolerable upper limit has been set because toxicity from dietary or supplemental K is rare. But there is one major, non-negotiable exception.

If you take warfarin (Coumadin) or another vitamin K antagonist blood thinner, do not start a vitamin K2 supplement without your prescribing doctor’s explicit guidance. Warfarin works precisely by blocking vitamin K’s activation pathway. Adding vitamin K — including K2 — can counteract the drug and change how thin your blood is, which can be dangerous. The standard medical advice for people on warfarin is to keep vitamin K intake consistent day to day rather than swinging it up or down, because both spikes and sudden drops can destabilize anticoagulation. A new supplement is exactly the kind of change that must be managed by your care team and monitored with INR testing.

Note that the newer direct oral anticoagulants (such as apixaban or rivaroxaban) do not work through the vitamin K pathway, so they are generally not affected the same way — but you should still confirm with your own physician. Anyone with a bleeding or clotting disorder, or who is pregnant or breastfeeding, should also check with a clinician before supplementing.

Frequently Asked Questions

What does vitamin K2 do?

Vitamin K2 activates two key proteins: osteocalcin, which helps bind calcium into bone, and matrix Gla protein, which helps prevent calcium from depositing in artery walls. In essence, it helps direct calcium to where it belongs (bones) and away from where it can cause harm (arteries). It also contributes to normal blood clotting.

Should I take K2 with D3?

They pair well biologically. Vitamin D3 increases how much calcium you absorb, while K2 helps activate the proteins that route that calcium into bone and away from arteries. Many people take a combined D3 + K2 supplement for this reason. The pairing is mechanistically sensible, though large trials proving the combination reduces fractures or heart attacks in the general population are still limited.

What foods are high in vitamin K2?

By far the richest source is natto, a fermented soybean dish (roughly 900–1,200 mcg per 100 g). After that come aged cheeses (around 50–75 mcg per 100 g), egg yolks, butter, and some fatty meats and liver. Because most Western diets contain little natto, getting meaningful K2 from food alone is difficult for many people.

MK-4 or MK-7 — which is better?

MK-7 is generally preferred for supplements because it stays in the bloodstream far longer (a half-life of days versus hours for MK-4), allowing effective once-daily dosing. The most-cited bone and arterial trials used MK-7 at 180 mcg/day. MK-4 is more common in food and requires more frequent, higher dosing to maintain blood levels.

Is vitamin K2 safe with blood thinners?

Not without medical supervision if you take warfarin or another vitamin K antagonist. Vitamin K, including K2, can counteract warfarin and change how thin your blood is. If you are on warfarin, do not start K2 without your doctor’s guidance and INR monitoring. Newer direct oral anticoagulants (like apixaban or rivaroxaban) generally do not interact the same way, but confirm with your physician.

How much vitamin K2 should I take?

The most-studied supplemental dose is MK-7 at about 90–180 mcg per day, which matches what the multi-year bone and arterial trials used. There is no established upper limit due to K2’s low toxicity, but the goal is a consistent, sensible dose rather than a megadose. Always talk to your doctor if you have a medical condition or take medication.

Does vitamin K2 reverse artery calcification?

The honest answer is: not proven. Observational data (like the Rotterdam Study) link higher K2 intake to less calcification and lower heart disease mortality, and randomized trials show K2 improves surrogate markers such as arterial stiffness and activated matrix Gla protein. But we do not yet have large trials proving K2 reverses existing calcification or prevents heart attacks in the general population. The evidence is promising and mechanism-consistent, not conclusive.

Can I get enough K2 from a healthy diet?

Possibly, if you regularly eat natto or large amounts of aged cheese and pastured animal products. For most people who do not, dietary K2 tends to be low. This is one reason supplementation is popular, though a nutrient-dense diet should always come first.

The Bottom Line

Vitamin K2 is a genuinely under-appreciated nutrient with a coherent, well-understood mechanism: it activates the proteins that route calcium into bone and away from arteries. The bone evidence is the strongest, anchored by multi-year randomized trials of MK-7 at 180 mcg/day showing slowed bone loss and improved bone-strength markers in postmenopausal women. The heart evidence is promising but softer — a compelling ~50% lower coronary heart disease mortality signal in the observational Rotterdam Study, backed by randomized improvements in arterial stiffness, but not yet proven at the level of preventing heart attacks.

For most people, K2 is a low-risk, biologically sensible addition — especially as MK-7 paired with vitamin D3, from a third-party-tested product, taken with a meal. The one firm rule: if you take warfarin or another vitamin K antagonist, do not supplement without your doctor’s oversight. As with any nutrient, food first, supplements second, and your physician in the loop when medications or medical conditions are involved.

Sources

1. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study. The Journal of Nutrition. 2004;134(11):3100–3105. https://pubmed.ncbi.nlm.nih.gov/15514282/
2. Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International. 2013;24(9):2499–2507. https://pubmed.ncbi.nlm.nih.gov/23525894/
3. Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: A double-blind randomised clinical trial. Thrombosis and Haemostasis. 2015;113(5):1135–1144. https://pubmed.ncbi.nlm.nih.gov/25694037/
4. Rønn SH, Harsløf T, Oei L, Pedersen SB, Langdahl BL. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia: a 3-year randomized, placebo-controlled clinical trial. Osteoporosis International. 2021;32(1):185–191. https://pubmed.ncbi.nlm.nih.gov/33030563/
5. Schurgers LJ, Cranenburg ECM, Vermeer C. Matrix Gla-protein: The calcification inhibitor in need of vitamin K. Thrombosis and Haemostasis. 2008;100(4):593–603. https://pubmed.ncbi.nlm.nih.gov/18841280/
6. Office of Dietary Supplements, National Institutes of Health. Vitamin K — Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/